|Bid||77.00 x 800|
|Ask||950.00 x 1100|
|Day's Range||882.15 - 906.15|
|52 Week Range||560.65 - 948.03|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||46.68|
|Forward Dividend & Yield||5.40 (0.61%)|
|1y Target Est||N/A|
ALLEN, Texas, May 08, 2019 -- Atrion Corporation (Nasdaq - ATRI) today announced revenues for the quarter ended March 31, 2019 were $41.6 million compared with $39.4 million in.
ALLEN, Texas, Feb. 26, 2019 -- Atrion Corporation (NASDAQ: ATRI) announced today that for the fourth quarter of 2018 revenues were $34.9 million compared to $34.0 million in.
ALLEN, Texas, Feb. 26, 2019 -- Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors declared a quarterly dividend of $1.35 per share on its outstanding.
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ALLEN, Texas, Nov. 09, 2018 -- Atrion Corporation (NASDAQ: ATRI) today announced that for the third quarter ended September 30, 2018 revenues totaled $39.3 million, up from.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on TransEnterix, Inc. (NYSE: TRXC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TRXC as the Company's latest news hit the wire. On May 29, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for expanded indications of the Company's Senhance Surgical System for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.